Detalhe da pesquisa
1.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Lancet
; 400(10366): 1869-1881, 2022 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36354040
2.
Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium "Long-Acting Injectables" Working Group.
Pharm Res
; 40(7): 1601-1631, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36811809
3.
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.
JAMA
; 330(11): 1042-1053, 2023 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37638695
4.
A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
Diabetes Obes Metab
; 24(2): 239-246, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34647404
5.
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Diabetes Obes Metab
; 22(10): 1886-1891, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32519795
6.
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Diabetes Obes Metab
; 22(6): 938-946, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31984598
7.
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Lancet
; 392(10160): 2180-2193, 2018 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30293770
8.
The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
Diabetes Obes Metab
; 25(9): 2784-2788, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311727
9.
Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.
Br J Clin Pharmacol
; 81(5): 958-70, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26580489
10.
Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
Invest New Drugs
; 32(1): 123-34, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23579358
11.
Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.
Int J Gynecol Cancer
; 24(3): 528-33, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24557436
12.
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.
CPT Pharmacometrics Syst Pharmacol
; 13(3): 494-503, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356317
13.
Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
Curr Med Res Opin
; 40(4): 567-574, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38407177
14.
Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies.
J Clin Endocrinol Metab
; 109(2): 361-369, 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37700637
15.
Effects of Tirzepatide vs Semaglutide on ß-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.
J Clin Endocrinol Metab
; 2024 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38795393
16.
A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes.
Adv Ther
; 40(8): 3434-3445, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285081
17.
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Diabetes Care
; 46(5): 998-1004, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36857477
18.
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
Invest New Drugs
; 30(6): 2344-51, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22160854
19.
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Clin Pharmacokinet
; 61(7): 1057-1067, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35674880
20.
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Lancet Diabetes Endocrinol
; 10(6): 418-429, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35468322